These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 23346859)

  • 41. [Extended-spectrum beta-lactamases: their role in clinical microbiology laboratory, treatment and infection control].
    Dolapçi I
    Mikrobiyol Bul; 2005 Apr; 39(2):229-40. PubMed ID: 16128036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extended-spectrum beta-lactamase-producing organisms.
    Falagas ME; Karageorgopoulos DE
    J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens.
    Helfand MS; Bonomo RA
    Curr Opin Pharmacol; 2005 Oct; 5(5):452-8. PubMed ID: 16084766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis of antibiotic resistance and genotypes on extended spectrum β-lactamase and AmpC β-lactamase producing strains isolated from Uygur and Han newborns].
    Zhang WL; Liu J; Zhang J; Su GL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Mar; 45(3):217-24. PubMed ID: 21624232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
    Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiology of β-Lactamase-Producing Pathogens.
    Bush K; Bradford PA
    Clin Microbiol Rev; 2020 Mar; 33(2):. PubMed ID: 32102899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bacterial resistance mechanisms to beta-lactam antibiotics: assessment of management strategies.
    Dudley M
    Pharmacotherapy; 1995; 15(1 Pt 2):9S-14S. PubMed ID: 7753692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid characterization of beta-lactamases by multiplex PCR.
    Woodford N
    Methods Mol Biol; 2010; 642():181-92. PubMed ID: 20401595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D).
    Romero E; Oueslati S; Benchekroun M; D'Hollander ACA; Ventre S; Vijayakumar K; Minard C; Exilie C; Tlili L; Retailleau P; Zavala A; Elisée E; Selwa E; Nguyen LA; Pruvost A; Naas T; Iorga BI; Dodd RH; Cariou K
    Eur J Med Chem; 2021 Jul; 219():113418. PubMed ID: 33862516
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of extended-spectrum beta-lactamases in South America.
    Villegas MV; Kattan JN; Quinteros MG; Casellas JM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():154-8. PubMed ID: 18154539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IRT and CMT beta-lactamases and inhibitor resistance.
    Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Appearance of extended-spectrum beta-lactamases].
    Iyobe S
    Nihon Rinsho; 1997 May; 55(5):1219-24. PubMed ID: 9155178
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Beta-lactamases of Gram negative bacteria: never-ending clockwork!].
    Philippon A; Arlet G
    Ann Biol Clin (Paris); 2006; 64(1):37-51. PubMed ID: 16420989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia.
    Kader AA; Kumar AK
    Saudi Med J; 2004 May; 25(5):570-4. PubMed ID: 15138522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.
    Hirsch EB; Tam VH
    J Antimicrob Chemother; 2010 Jun; 65(6):1119-25. PubMed ID: 20378670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum beta-lactamases.
    Walther-Rasmussen J; Høiby N
    Can J Microbiol; 2004 Mar; 50(3):137-65. PubMed ID: 15105882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carbapenemases: Partners in crime.
    Bush K
    J Glob Antimicrob Resist; 2013 Mar; 1(1):7-16. PubMed ID: 27873609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metallo-beta-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily.
    Bebrone C
    Biochem Pharmacol; 2007 Dec; 74(12):1686-701. PubMed ID: 17597585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Beta-lactamases: a survey of protein diversity.
    Helfand MS; Bonomo RA
    Curr Drug Targets Infect Disord; 2003 Mar; 3(1):9-23. PubMed ID: 12570729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.